AI assistant
Cipla Ltd. — Capital/Financing Update 2025
Feb 3, 2025
59275_rns_2025-02-03_0bb52a7d-af23-4a7b-8d21-b374c22e729b.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [84 x 30] intentionally omitted <==
3[rd] February 2025
(1) BSE Limited (2) National Stock Exchange of India Limited Listing Department, Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5[th] floor, Dalal Street, Plot no. C/1, G Block, Mumbai 400 001 Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Scrip Code: 500087 Scrip Code: CIPLA
(3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg
Sub: Investment in Cipla Medpro South Africa Proprietary Limited, wholly owned subsidiary
Dear Sir/Madam,
In compliance with the provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), we hereby notify that the Company will invest approx. ZAR 900 million in equity share capital of Cipla Medpro South Africa Proprietary Limited, a wholly-owned subsidiary of the Company in South Africa (“CMSA”).
Details required to be disclosed under the Listing Regulations read with Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11[th] November 2024 on the captioned subject are enclosed to this letter.
We request you to kindly take the above disclosure on record.
Thanking you, Yours faithfully,
For Cipla Limited RAJENDR Digitally signed by RAJENDRA A KUMAR KUMAR CHOPRA Date: 2025.02.03 CHOPRA 15:29:16 +05'30' Rajendra Chopra Company Secretary
Prepared by: Akshaya Kolvankar
Cipla Ltd. Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India P +91 22 41916000 F +91 22 41916120 W www.cipla.com E-mail [email protected] Corporate Identity Numbe r L24239MH1935PLC002380
==> picture [84 x 30] intentionally omitted <==
Annexure – I
Details as per the SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11[th] November 2024
| Sr. No. |
Particulars | Details |
|---|---|---|
| a) | Name of the target entity, details in brief such as size, turnover, etc. |
Cipla Medpro South Africa Proprietary Limited (“CMSA”) CMSA, is a wholly owned subsidiary of Cipla Limited, and is the holding company for the group operations in South Africa. The group is involved in the manufacturing, marketing, and supply of pharmaceutical products. Turnover as on 31stMarch 2024: ZAR 688.28 million |
| b) | Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length” |
The transaction is a related party transaction and will be at arm’s length. None of the promoter/promoter group/group companies have any interest in the entity. |
| c) | Industry to which the entity being acquired belongs |
Pharmaceutical |
| d) | Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity) |
The investment will be utilised to reduce inter-group debt and improve the capital structure of CMSA and its subsidiaries. |
| e) | Brief details of any governmental or regulatory approvals required for the acquisition |
Not Applicable. |
| f) | Indicative time-period for completion of the acquisition |
The investment is expected to be completed on or before 28thFebruary 2025 or such other date mutually agreed between the parties. |
| g) | Consideration - whether cash consideration or share swap or any other form and details of the same |
Cash consideration. |
Cipla Ltd.
Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India
P +91 22 41916000 F +91 22 41916120 W www.cipla.com E-mail [email protected] Corporate Identity Numbe r L24239MH1935PLC002380
==> picture [84 x 30] intentionally omitted <==
| h) | Cost of acquisition and/or the price at which the shares are acquired |
Cost of acquisition: ZAR 899,999,992 Number of equity shares: 40,742,417 |
|
|---|---|---|---|
| i) | Percentage of shareholding / control acquired and / or number of shares acquired |
||
| j) | Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years’ turnover, country in which the acquired entity has presence and any other significant information (in brief) |
Brief background: Refer (a) above. Date of Incorporation: 15thJuly 2013 History of last 3 years turnover: FY Turnover FY 2023-24 ZAR 688.28 million FY 2022-23 ZAR 1.12 billion FY 2021-22 ZAR 1.71 billion Country in which CMSA has its presence: South Africa |
Cipla Ltd.
Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India P +91 22 41916000 F +91 22 41916120 W www.cipla.com E-mail [email protected] Corporate Identity Numbe r L24239MH1935PLC002380